Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The first study, Javelin Gastric 100, will compare the switch from first-line chemotherapy to maintenance therapy with avelumab versus continuation of chemotherapy. It will evaluate the potential superiority
STARTRK-NG (which stands for "Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation") is a multicenter, open label, dose-escalation and expansion study designed to determine
The agreement creates opportunities for scientists at Princeton University and Bristol-Myers Squibb to collaborate on top-flight synthetic chemistry research, leveraging the two sites’ close proximity to foster a
Celldex previously announced the collaboration with Roche to evaluate the novel immunotherapy combination in March 2015. Under the terms of the agreement, Roche will provide atezolizumab, and Celldex
In each of these collaborations, Adimab will use its proprietary yeast-based discovery platform to generate IgGs for development as therapeutic products. MD Anderson and Memorial Sloan Kettering retain
The company has also secured an additional $2 million optional financing commitment in this series. Panacea Pharmaceuticals chairman & CEO/CSO Hossein Ghanbari said: "Our lead drug candidate, our
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.